Cue Biopharma to Host Business Update Call and Webcast

Rhea-AI Summary

Cue Biopharma (Nasdaq: CUE), a clinical-stage biopharmaceutical company, has announced a business update conference call and webcast scheduled for Tuesday, April 15, 2025, at 4:30 p.m. ET. The company, which focuses on developing therapeutic biologics for cancer and autoimmune disease treatment through selective T cell engagement and modulation, will make the presentation available to investors through multiple channels.

Access details include:

• Domestic investors: 1-844-826-3035
• International investors: 1-412-317-5195
• Conference ID: 10199037

The webcast will be accessible through the company's Investors and Media section and will remain archived for 30 days following the presentation.

News Market Reaction – CUE

+1.14%

1 alert

+1.14% News Effect

On the day this news was published, CUE gained 1.14%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

BOSTON, April 14, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that it will host a conference call and webcast to provide a business update on Tuesday, April 15, 2025 at 4:30 p.m. ET.

Conference Call and Webcast Details
Tuesday, April 15 at 4:30 p.m. ET

Investors:	1-844-826-3035
International Investors:	1-412-317-5195
Conference ID:	10199037
Webcast Link:	https://viavid.webcasts.com/starthere.jsp?ei=1715808&tp_key=9378826572

The live and archived webcast will also be available in the Investors and Media section of the Company’s website. The webcast will be archived for 30 days.

About Cue Biopharma
Cue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body. The company’s proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body’s intrinsic immune system through the selective modulation of disease-specific T cells without the adverse effects of broad systemic immune modulation.

Headquartered in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and protein engineering as well as the design and clinical development of protein biologics.

For more information please visit www.cuebiopharma.com and follow us on X and LinkedIn.

Investor Contact
Marie Campinell 
Senior Director, Corporate Communications
Cue Biopharma, Inc.
mcampinell@cuebio.com

Media Contact
Jonathan Pappas
LifeSci Communications
jpappas@lifescicomms.com

FAQ

When is Cue Biopharma's (CUE) upcoming business update call in April 2025?

Cue Biopharma's business update call is scheduled for Tuesday, April 15, 2025, at 4:30 p.m. ET.

How can investors access Cue Biopharma's (CUE) April 2025 business update webcast?

Investors can access the webcast through the company's Investors and Media section or via https://viavid.webcasts.com with conference ID 10199037.

What is the dial-in number for international investors for CUE's April 2025 update call?

International investors can dial 1-412-317-5195 to access the call.

How long will Cue Biopharma's (CUE) April 2025 business update webcast be available?

The webcast will be archived and available for 30 days following the presentation.

What therapeutic areas does Cue Biopharma (CUE) focus on developing treatments for?

Cue Biopharma focuses on developing therapeutic biologics for the treatment of cancer and autoimmune disease through T cell engagement and modulation.